These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2006-001084-27 Phase I/II study of prevention of Colorectal Cancer CRC with Allopurinol in High-Risk Subjects not-yet-due
Ongoing 2007-007740-10 Randomized placebo-controlled phase III trial of low-dose tamoxifen women whit IntraEphitelial Neoplasia(IEN) not-yet-due
Ongoing 2008-005206-39 Pilot Study: Iron-chelating treatment in patients with Neurodegeneration with Brain Iron Accumulation (NBIA). not-yet-due
Ongoing 2009-010088-17 Whole liver iron overload measured by the biosusceptometer Magnetic Iron Detector (MID) in thalassemia and MDS patients treated with deferasirox not-yet-due
Ongoing 2010-018456-27 Efficacia diagnostica della metodica 18F-DOPA-PET/TC nello studio del Neuroblastoma: confronto con scintigrafia 123I-MIBG. not-yet-due
Ongoing 2012-005398-30 Diagnostic efficacy and prognostic method [18F] DOPA-PET/CT in study of neuroblastoma: comparison with 123I-MIBG scintigraphy Efficacia diagnostica e prognostica della metodica [18F]DOPA-PET/CT nel... not-yet-due
Ongoing 2013-000287-29 EARLY PREDICTION OF EFFICACY OF ENDOCRINE THERAPY IN BREAST CANCER: PILOT STUDY AND VALIDATION WITH 18F FLUOROESTRADIOL (FES) PET/CT not-yet-due
Completed, but no date, and reported results 2014-005140-18 Diagnostic and clinical value of fused 64CuCl2-PET/MRI in prostate cancer relapse. Comparison with multiparametric MRI (mMRI) and 18F-Choline-PET/MRI Efficacia diagnostica e impatto clinico della ... bad-data
Ongoing 2015-004824-77 A randomized, phase II, double-blind, placebo-controlled, multicenter, 2x2 factorial design biomarker tertiary prevention trial of low-dose aspirin and metformin in resected stage I-III colorectal can... not-yet-due
Not reported Terminated 2018-000693-30 EXemestane in Progesterone and/or Estrogen receptor positive epithelial ovarian cancer. A Randomized phase III Trial, EXPERT. EXemestane in Progesterone and/or Estrogen receptor positive epithelial... 2022-11-24 due-trials
Ongoing 2018-004667-30 Diagnostic and clinical value of 64CuCl2 in HGG/DIPG Ruolo diagnostico e aspetti dosimetrici del 64CuCl2 nei Gliomi infiltranti ad alto grado dell’età pediatrica not-yet-due
Ongoing 2019-001447-40 Pilot Study of Daily Exemestane in Women with Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer Studio pilota con exemestane gi... not-yet-due
Ongoing 2019-002534-37 Diagnostic and predictive role of 64CuCl2 PET / CT in bladder cancer patients eligible for chemotherapy Ruolo diagnostico e predittivo della 64CuCl2 PET/CT nei pazienti affetti da tumore della vesc... not-yet-due
Ongoing 2020-002468-30 Study of Metformin activity in patients with differentiated thyroid cancer metastasis with minimally progressive development Studio sull’attività della Metformina nei pazienti affetti da metastasi ... not-yet-due
Ongoing 2020-003066-39 Letrozole for Estrogen/Progesterone Receptor positive low-grade serous Epithelial ovarian cancer. A randomized phase III trial. LEPRE Trial Letrozolo per il trattamento del carcinoma ovarico epitel... not-yet-due
Ongoing 2021-000134-34 Time restricted Eating And Metformin (TEAM) in invasive breast cancer (IBC) or ductal carcinoma in situ (DCIS). A randomized, phase IIb, window of opportunity presurgical trial. Digiuno intermitten... not-yet-due